[Hengrui Pharmaceuticals: Subsidiary's raciximab for injection has been approved for clinical trials] On September 15th, Hengrui Pharmaceuticals (600276.SH) announced that the company's subsidiary Guangdong Hengrui Pharmaceutical has received the approval from the State Food and Drug Administration to issue a "Drug Clinical Trial Approval Notice" for raciximab for injection, and agreed to conduct a Phase III clinical trial for adult patients with intracranial atherosclerotic stenosis to reduce the risk of recurrence of stroke. The drug is an anti-PCSK9 monoclonal antibody independently developed by the company. It has been approved for marketing in China in 2025. The cumulative investment in research and development of related projects is approximately 422 million yuan.